CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Bolt Biotherapeutics, Inc. - BOLT CFD

0.6235
1.89%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0146
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024124 %
Charges from full value of position ($-4.58)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024124%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001901 %
Charges from full value of position ($0.36)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001901%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 0.6355
Open 0.6185
1-Year Change -29.06%
Day's Range 0.6185 - 0.6435
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Nov 29, 2024 0.6354 0.0270 4.44% 0.6084 0.6355 0.6035
Nov 27, 2024 0.6117 0.0061 1.01% 0.6056 0.6272 0.5984
Nov 26, 2024 0.6230 0.0546 9.61% 0.5684 0.6385 0.5684
Nov 25, 2024 0.5984 0.0420 7.55% 0.5564 0.6052 0.5564
Nov 22, 2024 0.5768 0.0184 3.30% 0.5584 0.5785 0.5502
Nov 21, 2024 0.5584 0.0100 1.82% 0.5484 0.5784 0.5484
Nov 20, 2024 0.5584 0.0100 1.82% 0.5484 0.5697 0.5484
Nov 19, 2024 0.5584 0.0100 1.82% 0.5484 0.5777 0.5384
Nov 18, 2024 0.5570 -0.0014 -0.25% 0.5584 0.5684 0.5384
Nov 15, 2024 0.5634 -0.0460 -7.55% 0.6094 0.6094 0.5584
Nov 14, 2024 0.6134 -0.0045 -0.73% 0.6179 0.6234 0.6084
Nov 13, 2024 0.6085 -0.0300 -4.70% 0.6385 0.6385 0.6084
Nov 12, 2024 0.6344 0.0000 0.00% 0.6344 0.6505 0.6344
Nov 11, 2024 0.6334 0.0020 0.32% 0.6314 0.6334 0.6314
Nov 8, 2024 0.6314 -0.0270 -4.10% 0.6584 0.6584 0.6284
Nov 7, 2024 0.6495 0.0105 1.64% 0.6390 0.6619 0.6390
Nov 6, 2024 0.6385 -0.0004 -0.06% 0.6389 0.6484 0.6284
Nov 5, 2024 0.6561 0.0005 0.08% 0.6556 0.6663 0.6484
Nov 4, 2024 0.6561 0.0177 2.77% 0.6384 0.6561 0.6284
Nov 1, 2024 0.6484 0.0200 3.18% 0.6284 0.6541 0.6284

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Bolt Biotherapeutics, Inc. Company profile

About Bolt Biotherapeutics Inc

Bolt Biotherapeutics, Inc is a clinical-stage immuno-oncology company. The Company is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Its Immune-Stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells, including macrophages and dendritic cells, that kill tumor cells via phagocytosis and expose tumor neoantigens to the adaptive immune system. The Company’s product candidate BDC-1001 is a human epidermal growth factor receptor 2 (HER2) Boltbody ISAC comprised of a HER2-targeting biosimilar, of trastuzumab conjugated to one of its TLR7/8 agonists, for the treatment of patients with HER2-expressing solid tumors, including those with HER2-low tumors. Its Toll-like receptors (TLRs) activate myeloid cells and enable the presentation of tumor-associated neoantigens to cytotoxic T cells.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Bolt Biotherapeutics Inc revenues increased from $231K to $752K. Net loss increased from $29.7M to $71.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and d increase of 99% to $49.8M (expense), Fair Value Adjustments on Other Assets decrease from $2.4M (income) to $6.1M (expense).

Industry: Bio Therapeutic Drugs

900 Chesapeake Drive
REDWOOD CITY
CALIFORNIA 94063
US

News

SHIB cryptocurrency logo, showing a cartoon Shiba Inu dog on a coin, over a golden orange background with circuit board graphics detail

Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target

Can Shiba Inu reinvent itself to become a worthy long-term investment?

16:41, 28 November 2024
Gold bars on a black background with a diagram

Gold price predictions for the next five years: Third party data round up

Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.

15:17, 18 November 2024

Trump trades charge as Bitcoin hits $US80,000

Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.

10:48, 13 November 2024

Australian jobs data expected to point to solid labour market conditions

Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.

10:16, 13 November 2024

FOMC cuts interest rates as expected and sticks to its line on future policy

The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.

13:33, 8 November 2024

FOMC and BOE preview: further rate cuts expected

Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.

14:14, 5 November 2024

RBA meeting preview: No change to policy expected as inflation fight continues

The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.

13:35, 4 November 2024

People also watch

Gold

2,639.11 Price
-0.400% 1D Chg, %
Long position overnight fee -0.0168%
Short position overnight fee 0.0086%
Overnight fee time 22:00 (UTC)
Spread 0.30

ETH/USD

3,607.52 Price
-2.670% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

BTC/USD

95,746.60 Price
-2.170% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

XRP/USD

2.76 Price
+26.890% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01375

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading